Serum galactosyltransferase activity with three acceptors in ovarian cancer patients.
Several laboratories have demonstrated the usefulness of serum galactosyltransferase as a biological marker for ovarian neoplasms. However, contradictory results have been published recently, which might be partially explained by differences in methodology. We thus decided to measure serum galactosyltransferase activity in patients with ovarian cancer and benign gynecological diseases using three different assay systems. A very good correlation was obtained between the results of these assays. Furthermore, we confirm that serum GT is frequently elevated in cancer patients, and is of potential value for their follow-up.
Gauduchon
P
P
Laboratoire de Biochimie, U.F.R. des Sciences Pharmaceutiques, Caen, France.
Bar
E
E
Malas
J P
JP
Aubert
M
M
Sichel
F
F
Le Talaër
J Y
JY
D000117:Acetylglucosamine / Q000378:metabolism; D001212:Asialoglycoproteins; D005260:Female; D060748:Fetuins; D005700:Galactosyltransferases / Q000097:blood*; D006801:Humans; D008722:Methods; D010051:Ovarian Neoplasms / Q000201:enzymology*; D010059:Ovomucin / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000378:metabolism
D001212:Asialoglycoproteins; D060748:Fetuins; D000509:alpha-Fetoproteins; C017029:asialofetuin; D010059:Ovomucin; D005700:Galactosyltransferases; D000117:Acetylglucosamine